VIVES is a multi-sector fund that invests in projects with a positive societal impact
IntoPIX is an independent and innovative technology provider with world-class expertise and knowledge in video processing and compression, cryptography, high performance computing and microelectronics...
3D-Side assists surgeons by integrating 3D technologies into the operating room. We combine the precision of engineering with medical expertise to individualize the surgical treatment of each patient....
Founded in 2013 by Dr. Denis Dufrane and Dr. Jean-François Pollet, Novadip Biosciences is a spin-off from the University of Louvain (UCLouvain) and Saint-Luc University Clinics focusing on...
Denis Périquet, CEO Tessares :
"VIVES supports real innovation projects, while understanding that those projects need time to grow from the academic research phase to a commercial success. Team...
Pierre Blondeau, CEO Upstreem :
"We have been working since 2017 with VIVES II, which has joined us since the beginning of our adventure. VIVES II team has an in-depth understanding of all aspects of...
Willem de Vos, Professor at University of Wageningen ; Patrice Cani, Professor at UCLouvain ; Jean-Christophe Malrieu, CEO A-Mansia :
"As founders and CEO of A-mansia Biotech we experienced essential...
Louvain-la-Neuve, 22 October 2021 – VOCSens raises €2.5 million in seed funding in order to industrialise its gas microsensors. The objective? The aim is to commercialise its micro gas sensors in the
Belgian biotechnology company ViroVet partnered with researchers at The Pirbright Institute in 2019 to develop and test the first antiviral drugs that act against African swine fever (ASF). In the
European first in next-generation bacterium: pasteurized Akkermansia muciniphila from A-Mansia Biotech receives the green light from EFSA's scientific committee.
Excellent news for people at risk of